In a Big Relief for 340B Providers, Sen. Thune Will Run Again

U.S. Sen. John Thune (S.D.), a staunch 340B provider ally and the Senate’s No. 2 Republican, announced over the weekend he will seek re-election in November.

340B providers are sighing relief after U.S. Sen. John Thune (S.D.), a staunch 340B provider ally and the Senate’s No. 2 Republican, announced over the weekend he will seek re-election in November.

Please Login or Become

Read More »

N.Y. State and Va. Health Centers Ask Fed. Judge to Let their 340B-Related Antitrust Suit Against Drug Makers Go on

New York state health center Mosaic Health and its co-plaintiff Central Virginia Health Services are opposing four insulin and diabetes drug manufacturers’ motion to dismiss their antitrust class action over the companies’ denials of 340B pricing when covered entities use contract pharmacies.

New York state and Virginia health centers on Friday asked a federal district judge to deny four insulin and diabetes drug manufacturers’ motion to dismiss the health centers’ antitrust class action over the companies’ denials of 340B pricing when covered

Read More »

Appeals Court Signals it Might Send Lilly’s 340B Lawsuit Back to Lower Court

A federal circuit court has suspended Lilly’s 340B contract pharmacy lawsuit on technical grounds and might send it back to a lower court.

A federal circuit court on Tuesday halted drug manufacturer Lilly and the federal government’s appeals of a district judge’s late October ruling in Lilly’s 340B contract pharmacy lawsuit, on technical grounds.

Please Login or Become a

Read More »

Judge in AstraZeneca’s 340B Case, on Verge of Big Promotion, Gives Parties Just Two Days for a Status Report

The judge in AstraZeneca’s 340B contract pharmacy lawsuit, who could be elevated soon to a federal appeals court, indicated this week that his decision in the case is still in progress.

The judge in AstraZeneca’s 340B contract pharmacy lawsuit yesterday ordered both sides to file a joint status report by no later than Friday—a sign, lawyers say, that his decision in the case is still in progress.

Read More »

Drug Makers Want to Halt 340B Dispute Resolution Proceedings, Citing Lawsuits and Forthcoming Rule

Timeout
AstraZeneca and Sanofi have asked 340B administrative dispute resolution panels to pause covered entities’ ADR proceedings against them.

Drug manufacturers AstraZeneca and Sanofi have asked 340B administrative dispute resolution panels to pause covered entities’ ADR proceedings against them until all 340B-related federal court litigation is finished and until after the government finalizes its forthcoming new 340B ADR regulation.

Read More »

Feds Back and Kalderos Resists Pausing Company’s 340B Lawsuit

Kalderos says in a lawsuit that the federal government's 340B contract pharmacy policy is keeping it from effectively marketing its 340B Pay service to let drug companies provide 340B pricing as a post-purchase rebate rather than as a price discount.

The federal government told a judge in late December its appeal of her joint ruling in Novartis and United Therapeutics’ (UT) 340B contract pharmacy lawsuits justifies her pausing drug industry vendor Kalderos’ 340B contract pharmacy suit.

Read More »

Biden Axing Trump’s “Most Favored Nation” Drug Pricing Rule that 340B Entities and Pharma Both Disliked

The Biden administration is rescinding ex-President Trump's unimplemented most favored nation drug pricing rule, which was disliked by 340B entities and drug manufacturers.

The Biden administration is rescinding an unimplemented Trump-era regulation that would have pegged Medicare Part B drug reimbursement for 50 expensive, physician-administered drugs on the lowest price that drug manufacturers provide in similar countries.

Please Login

Read More »

Breaking News: AbbVie Becomes 11th Drug Maker to Restrict 340B Contract Pharmacy. Feds Appeal Rulings in Lilly, Novo Nordisk, and Sanofi Cases.

AbbVie is the 11th pharmaceutical maker to impose limits on 340B contract pharmacy.

AbbVie today announced conditions on 340B pricing when hospitals’ contract pharmacies dispense medicines to patients. The federal government has filed notices of appeal in Lilly, Novartis, Novo Nordisk, Sanofi, and United Therapeutics’ 340B contract pharmacy lawsuits.

Read More »

Breaking News: Feds Appeal Rulings in Novartis and United Therapeutics 340B Contract Pharmacy Cases

The federal government yesterday asked the federal appeals court in Washington, D.C., to review a lower court's Nov. 5 joint ruling in Novartis and United Therapeutics' 340B contract pharmacy lawsuits.

The federal government late yesterday filed notice that it is appealing a federal judge’s joint ruling in two cases last month that halted enforcement actions against two drug companies that deny 340B pricing when hospitals and other health care providers

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
×

*Sign up for news summaries and alerts from 340B Report